| Literature DB >> 32283773 |
Takemi Akahane1, Tadashi Namisaki1, Kosuke Kaji1, Kei Moriya1, Hideto Kawaratani1, Hiroaki Takaya1, Yasuhiko Sawada1, Naotaka Shimozato1, Yukihisa Fujinaga1, Masanori Furukawa1, Koh Kitagawa1, Takahiro Ozutsumi1, Yuuki Tsuji1, Daisuke Kaya1, Hiroyuki Ogawa1, Hirotetsu Takagi1, Koji Ishida1, Hitoshi Yoshiji1.
Abstract
We aimed to elucidate the effect of chronic alcohol consumption on fatty liver. We assessed the consumption of alcohol in 2429 Japanese males (mean age: 54.2 ± 9 years); they were classified according to average consumption into non-drinkers (ND), light drinkers (LD), moderate drinkers (MD), and heavy drinkers (HD). The prevalence of fatty liver was the lowest in the MD and highest in the ND group (p < 0.001), while obesity was not significantly different among the groups (p = 0.133). Elevated levels of alanine aminotransferase (ALT) were the lowest in the MD group (p = 0.011) along with resistance to insulin (homeostasis model assessment-insulin resistance (HOMA-IR)), which was highest in the ND group (p = 0.001). Chronic consumption of alcohol was independently and inversely associated with fatty liver and insulin resistance after adjusting for obesity, hypertension, fasting hyperglycemia, habit of drinking sweet beverages, physical activity, and age (odds ratios are as follows: ND, 1; LD, 0.682; MD, 0.771; HD, 0.840 and ND, 1; LD, 0.724; MD, 0.701; HD, 0.800, respectively). We found that regardless of the type of alcoholic beverage, chronic consumption of alcohol is inversely associated with insulin resistance and fatty liver in Japanese males. This study had limitations, most notably the lack of investigation into diet and nutrition.Entities:
Keywords: alcohol consumption; fatty liver; insulin resistance
Mesh:
Substances:
Year: 2020 PMID: 32283773 PMCID: PMC7231020 DOI: 10.3390/nu12041036
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Clinical characteristics according to categories of consumption of alcohol.
| ND | LD | MD | HD | ||
|---|---|---|---|---|---|
| N (%) | 894 (36.8) | 857 (35.3) | 444 (18.3) | 234 (9.6) | |
| Alcohol consumption | 0 | 15.8 ± 5.9 | 41.6 ± 5.8 | 77.4 ± 18.8 | <0.001 |
| Age (y) | 53.4 ± 9.2 | 54.7 ± 9.8 | 54.7 ± 8.5 | 54.3 ± 8.5 | 0.016 |
| BMI (kg/m2) | 24.2 ± 3.4 | 23.9 ± 3.1 | 24.0 ± 3.0 | 24.4 ± 3.0 | 0.074 |
| Habit of drinking sweet beverages (%) | 322 (36) # | 248 (28.9) | 96 (21.6) § | 39 (16.7) § | <0.001 |
| Habit of eating greasy meat (%) | 322 (36) | 315 (36.8) | 184 (41.4) | 96 (41) | 0.162 |
| Physical activity (%) | 316 (35.3) § | 366 (42.7) # | 187 (42.1) | 84 (35.9) | 0.005 |
| Systolic BP | 127 ± 15 | 129 ± 14 | 131 ± 15 *** | 134 ± 14 *** | <0.001 |
| Diastolic BP | 78 ± 11 | 79 ± 11 | 82 ± 10 *** | 84 ± 11 *** | <0.001 |
| Hypertension (%) | 277 (31) § | 304 (35.5) | 191 (43) # | 137 (58.5) # | <0.001 |
| Use of antihypertensive medications | 165 (18.5) § | 173 (20.2) | 122 (27.5) # | 72 (30.8) # | <0.001 |
| AST (IU/L) | 24 ± 19 | 24 ± 7 | 26 ± 22 ** | 28 ± 14 *** | <0.001 |
| ALT (IU/L) | 30 ± 19 | 27 ± 15 ** | 27 ± 20 | 30 ± 20 | 0.001 |
| GGT (IU/L) | 34 ± 30 | 42 ± 36 * | 62 ± 53 *** | 96 ± 119 *** | <0.001 |
| Triglycerides (mg/dL) | 125 ± 86 | 123 ± 76 | 139 ± 103 * | 169 ± 148 *** | <0.001 |
| Total cholesterol (mg/dL) | 205 ± 33 | 207 ± 32 | 206 ± 32 | 207 ± 34 | 0.524 |
| HDL cholesterol (mg/dL) | 53 ± 13 | 56 ± 13 *** | 60 ± 15 *** | 61 ± 15 *** | <0.001 |
| LDL cholesterol (mg/dL) | 129 ± 29 | 127 ± 29 | 120 ± 31 *** | 116 ± 33 *** | <0.001 |
| Use of lipid-lowering medications (%) | 129 (14.4) | 94 (11.0) | 53 (11.9) | 21 (9.0) | 0.054 |
| Fasting glucose (mg/dL) | 103 ± 20 | 103 ± 20 | 105 ± 20 | 107 ± 21 | 0.24 |
| Use of antidiabetic medications (%) | 62 (6.9) | 47 (5.5) | 27 (6.1) | 15 (6.4) | 0.657 |
| HOMA-IR | 1.9 ± 1.7 | 1.6 ± 1.4 ** | 1.5 ± 1.0 *** | 1.6 ± 1.2 * | <0.001 |
| Metabolic syndrome (%) | 202 (22.6) | 172 (20.1) § | 111 (25.1) | 80 (34.2) # | <0.001 |
Quantitative variables are presented as mean ± standard deviation. CI, confidence interval; BMI, body mass index; BP, blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; HOMA-IR, homeostasis model assessment-insulin resistance. * p < 0.05 vs. ND; ** p < 0.005 vs. ND; *** p < 0.001 vs. ND. # adjusted standardized residual > 1.96; § adjusted standardized residual < −1.96.
Figure 1(A) Prevalence of fatty liver by categories of consumption of alcohol; (B) Prevalence of obesity by categories of consumption of alcohol; (C) Prevalence of elevated levels of ALT by categories of consumption of alcohol; (D) Prevalence of resistance to insulin by categories of consumption of alcohol. #adjusted standardized residual > 1.96; § adjusted standardized residual < −1.96.
Predictors of fatty liver.
| Odds Ratio (95% CI) | ||
|---|---|---|
| ND | 1 | |
| LD | 0.682 (0.549–0.846) | 0.001 |
| MD | 0.771 (0.675–0.880) | <0.001 |
| HD | 0.840 (0.749–0.941) | 0.003 |
Explanatory variables include age, obesity, hypertension, fasting hyperglycemia, habit of drinking sweet beverages, and physical activity. CI, confidence interval.
Predictors of resistance to insulin.
| Odds Ratio (95% CI) | ||
|---|---|---|
| ND | 1 | |
| LD | 0.724 (0.539–0.974) | 0.033 |
| MD | 0.701 (0.577–0.852) | <0.001 |
| HD | 0.800 (0.686–0.933) | 0.005 |
Explanatory variables include age, obesity, hypertension, fasting hyperglycemia, habit of drinking sweet beverages, and physical activity. CI, confidence interval.
Biological features of non-drinkers and various types of drinkers.
| ND | Mixed Drinkers | Beer Drinkers | Sake Drinkers | Shochu Drinkers | Whiskey Drinkers | Wine Drinkers | ||
|---|---|---|---|---|---|---|---|---|
| N (%) | 894 (36.8) | 349 (14.4) | 813 (33.5) | 103 (4.2) | 236 (9.7) | 17 (0.7) | 17 (0.7) | |
| Alcohol consumption | 0 | 54.3 ± 23.9 | 20.4 ± 13.8 | 32.9 ± 16.9 | 43.7 ± 26.2 | 33.4 ± 18.4 | 16.4 ± 18.2 | <0.001 |
| LD (%), | 0 | 29 (8.3), | 653 (80.3), | 49 (47.6), | 105 (44.5), | 7 (41.2), | 14 (82.4), | <0.001 |
| Age (y) | 53.4 ± 9.2 | 54.6 ± 8.3 | 53.2 ± 9.4 | 60.8 ± 8.3 | 56.9 ± 8.6 | 52.4 ± 9.2 | 56.8 ± 10.3 | <0.001 |
| BMI (kg/m2) | 24.2 ± 3.4 | 24.2 ± 3.0 | 23.9 ± 3.1 | 23.4 ± 2.5 | 24.1 ± 3.2 | 24.0 ± 3.2 | 23.8 ± 2.8 | 0.243 |
| AST (IU/L) | 24 ± 9 | 26 ± 26 * | 24 ± 9 | 27 ± 9 | 26 ± 9 | 22 ± 3 | 25 ± 8 | 0.004 |
| ALT (IU/L) | 30 ± 19 | 27 ± 22 | 28 ± 17 | 28 ± 15 | 27 ± 13 | 23 ± 8 | 24 ± 12 | 0.058 |
| GGT (IU/L) | 34 ± 30 | 66 ± 85 *** | 47 ± 49 *** | 59 ± 70 *** | 67 ± 67 *** | 42 ± 27 | 55 ± 51 | <0.001 |
| Triglycerides (mg/dL) | 125 ± 86 | 142 ± 102 | 129 ± 80 | 121 ± 79 | 152 ± 149** | 148 ± 114 | 119 ± 81 | 0.001 |
| Use of lipid-lowering medications (%) | 129 (14.4) | 34 (9.7) | 89 (10.9) | 11 (10.7) | 30 (12.7) | 1 (5.9) | 3 (17.9) | 0.193 |
| Fasting glucose (mg/dL) | 103 ± 20 | 105 ± 20 | 104 ± 21 | 102 ± 14 | 107 ± 18 | 100 ± 10 | 102 ± 10 | 0.156 |
| Use of antidiabetic medications (%) | 62 (6.9) | 18 (5.2) | 43 (5.3) | 3 (2.9) | 24 (10.4) | 0 (0) | 1 (5.9) | 0.061 |
| HOMA-IR | 1.9 ± 1.7 | 1.5 ± 1.1 ** | 1.6 ± 1.4 * | 1.3 ± 0.9 * | 1.5 ± 1.0* | 1.7 ± 1.0 | 1.7 ± 2.0 | <0.001 |
| Fatty liver (%) | 426 (47.7) | 139 (39.8) | 312 (38.4) | 37 (35.9) | 97 (41.1) | 6 (35.3) | 7 (41.2) | 0.005 |
CI, confidence interval; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, γ-glutamyl transferase; HOMA-IR, homeostasis model assessment-insulin resistance. * p < 0.05 vs. ND; ** p < 0.005 vs. ND; *** p < 0.001 vs. ND.
Prevalence of fatty liver in various types of drinkers.
| LD | MD | HD | |
|---|---|---|---|
| Mixed drinkers | 13/29 (44.8) | 76/187 (40.6) | 50/133 (37.6) |
| Beer drinkers | 254/653 (38.9) | 42/131 (32.1) | 16/29 (55.2) |
| Sake drinkers | 14/49 (28.6) | 15/43 (34.9) | 8/11 (72.7) |
| Shochu drinkers | 41/105 (39.0) | 32/74 (43.2) | 24/57 (42.1) |
| Whiskey drinkers | 3/7 (42.9) | 2/7 (28.6) | 1/3 (33.3) |
| Wine drinkers | 4/14 (28.6) | 2/2 (100) | 1/1 (100) |
| 0.665 | 0.215 | 0.119 |